Psoriasis: optimising patients’ quality of life in primary and community care settings
Intended for healthcare professionals
CPD    

Psoriasis: optimising patients’ quality of life in primary and community care settings

Lucy Moorhead Nurse consultant in inflammatory skin disease, Guy’s and St Thomas’ NHS Foundation Trust, London, England

Why you should read this article:
  • To increase your awareness of psoriasis as a multisystemic condition often accompanied by comorbidities

  • To enhance your understanding of nurses’ role in assessing, treating and supporting people with psoriasis

  • To count towards revalidation as part of your 35 hours of CPD, or you may wish to write a reflective account (UK readers)

  • To contribute towards your professional development and local registration renewal requirements (non-UK readers)

Psoriasis is a common, non-contagious chronic inflammatory skin condition that affects approximately 1.5% of the population. The most common type is plaque psoriasis, which presents as raised and scaly skin plaques. Psoriasis can have systemic manifestations, for example psoriatic arthritis, and it increases the risk of comorbidities such as cardiovascular conditions, metabolic syndrome, diabetes mellitus, obesity and inflammatory bowel disease. It also commonly affects patients’ mental health. Sites where psoriasis has a particularly high impact on patients include the face, scalp, palms, soles, flexures and genitals. Treatments range from topical preparations to biologics and vary depending on the severity of psoriasis and the extent of its effects on the patient’s life. Nurses in primary and community care are well placed to assess, treat, educate, support and refer patients, helping them to live their lives with minimal detrimental effects from their condition.

Primary Health Care. doi: 10.7748/phc.2024.e1839

Peer review

This article has been subject to external double-blind peer review and checked for plagiarism using automated software

@lucyronda

Correspondence

lucy.moorhead@gstt.nhs.uk

Conflict of interest

Lucy Moorhead has attended conferences, spoken at meetings and attended advisory boards for the following companies: AbbVie, Almirall, BMS, Janssen-Cilag, Leo, Lilly, Novartis, Pfizer, Sanofi, Recordati and UCB

Moorhead L (2024) Psoriasis: optimising patients’ quality of life in primary and community care settings. Primary Health Care. doi: 10.7748/phc.2024.e1839

Published online: 12 June 2024

Want to read more?

RCNi-Plus
Already have access? Log in

or

3-month trial offer for £5.25/month

Subscribe today and save 50% on your first three months
RCNi Plus users have full access to the following benefits:
  • Unlimited access to all 10 RCNi Journals
  • RCNi Learning featuring over 175 modules to easily earn CPD time
  • NMC-compliant RCNi Revalidation Portfolio to stay on track with your progress
  • Personalised newsletters tailored to your interests
  • A customisable dashboard with over 200 topics
Subscribe

Alternatively, you can purchase access to this article for the next seven days. Buy now


Are you a student? Our student subscription has content especially for you.
Find out more